In the present study, we isolated and determined the pharmacological characteristics of a novel gene encoding the light chain of human Ig surface antigen-related gene (IgLC-rG 
Introduction
The class of Igs is defined by the type of C H region. Igs are divided into five distinct isotypes: IgM, IgD, IgG, IgA, and IgE. Among them, IgM is the first Ig to be produced by any B cells, whereas IgG is the most abundant Ig that possesses the central ability to activate a complement. IgA is mainly produced by the tonsils and found in saliva. On the other hand, IgE is well known to be associated with allergic responses and defense against many kinds of allergens such as ticks, animal hairs, and exogenous drugs and chemicals. In general, these cell surface antigens are believed to be bound in the cellular plasma membrane.
It is well known that drug transporters play a pivotal role in the drug clearance of the liver, kidney, brain, placenta, and small intestine. Such transporters have been predicted to have several membrane-spanning domains and are known to be localized at the cellular surface (Hagenbuch and Meier, 2004; Sekine et al., 2006) . For example, the organic anion transporters [OATs/Oats (SLC22A)] and the organic anion-transporting polypeptides [OATPs/Oatps (SLC21/SLCO)] are predicted to be bound at the sinusoidal membrane of hepatocytes, apical membrane of ileocytes, and basolateral membrane of kidney proximal tubular cells, respectively, with 10 to 12 transmembrane domains (TMDs) Meier, 2003, 2004; Koepsell and Endou, 2004) . Likewise, the ATP-binding cassette (ABC) transporter family, such as multidrug resistance proteins, P-glycoprotein (ABCB1), and breast cancer resistance protein (ABCG2), is predicted to have 17, 12, and 6 TMDs, respectively (Leslie et al., 2005) . In addition, human organic solute carrier protein 1 is predicted to have 3 TDMs (Kobayashi et al., 2005) . The 4F2 cell surface antigen (CD98) is a heterodimeric protein composed of two subunits, an 80-kDa glycosylated heavy chain and a 40-kDa nonglycosylated light chain (Haynes et al., 1981; Hemler et al., 1982) . The 4F2hc antigen has been identified as a cell surface antigen and transport of a system b 0,ϩ -like amino acid (Wells et al., 1992) . The secondary structure model of 4F2hc is predicted to have a single transmembrane domain and is a transporter of amino acids when expressed in Xenopus oocytes (Wells et al., 1992; Kanai et al., 1998) . Likewise, related to b 0,ϩ amino acid transporter induces dibasic and neutral amino acids (Bertran et al., 1992a,b) . These membrane-bound proteins actively transport various kinds of drugs and chemicals, assuming that, at least in part, transmembrane signature(s) are a structural requirement for stimulating the transport of organic solutes.
CsA is a noncytotoxic immunosuppressant reagent and has been used for prophylaxis in organ transplantation. CsA has been also known to be a substrate of an ATP-dependent efflux transporter P-glycoprotein (Saeki et al., 1993) . In addition, CsA is involved in drug-drug interactions (Sparreboom and Nooter, 2000; Xia et al., 2007) , suggesting that there is some carrier protein responsible for CsA uptake; however, data concerning the uptake transporter for CsA are still limited.
In the present report, therefore, we describe the molecular cloning and functional characterization of a novel gene that belongs to the light chain of the human Ig surface antigen superfamily. We were surprised to find that an isolated gene, designated the light chain of human Ig surface antigen-related gene (IgLC-rG), stimulates the transport of CsA. Our results provide the first evidence of the transport of CsA via an Ig-related gene and IgLC-rG, which may be involved in CsA handling in the human body. ϩ RNA using the Superscript Choice System (Invitrogen, Carlsbad, CA). The constructed cDNA library was ligated into a phage vector ZipLox EcoRI arms (Invitrogen). An expressed sequence tag (EST) clone (GenBank/EMBL/DDBJ accession number BX327815) was identified and amplified by PCR and labeled with [␣- 32 P]dCTP by random priming ( T7 Quick Prime Kit; GE Healthcare). The library was screened with an EST clone as a probe under low stringency conditions. Replicate filters of a phage library were hybridized overnight in a hybridization solution (50% formamide, 5ϫ standard saline citrate (SSC), 3ϫ Denhardt's solution, 0.2% SDS, 10% dextran sulfate, 0.3 g/ml denatured salmon sperm DNA, 2.5 mM sodium pyrophosphate, 25 mM MES, and 0.03% Antifoam A, pH 6.5) at 37°C overnight. The filters were washed in 3ϫ SSC and 0.5% SDS at 37°C. cDNA inserts in a positive ZipLox phage were recovered in a plasmid pZL1 vector by in vitro excision.
Materials and Methods

Materials
DNA Sequence and Hydropathy Analysis. Double-stranded cDNA of isolated clones obtained from the library were sequenced in both directions. With use of a dye primer cycle sequencing kit (version 3.1; Applied Biosystems, Foster City, CA) and automated Applied Biosystems 310 DNA sequencer, deleted clones were made using a KiloSequence deletion kit (Takara, Tokyo, Japan). The sequence, the membrane topology, and the presence of possible signal peptides were assembled and analyzed using DNASIS-Pro (version 2.02; Hitachi Software Engineering, Kanagawa, Japan).
Northern Blotting Hybridization. A commercially available hybridization blot containing poly(A) ϩ RNA from various human tissues (Human MTN Blot I and II; Clontech, Mountain View, CA) and human cancer cell line MTN blots (Clontech) were used for the Northern blot analysis. These filters were hybridized at 42°C overnight in a hybridization solution (50% formamide) with full-length cDNA of IgLC-rG, which was randomly labeled with [ 32 P]dCTP as described above. The membrane was washed in 0.1ϫ SSC-0.1% SDS at 42°C.
Preparation of IgLC-rG cRNA and Transport Measurement. Stages V and VI defolliculated Xenopus oocytes were isolated from the female frog and used throughout this study. Xenopus oocytes were treated with collagenase A (2.0 mg/ml; Roche Diagnostics, Mannheim, Germany) in an oocyte Ringer's 2 solution (83 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES, pH 7.5) for at least 1 h at room temperature. The isolated clone, IgLC-rG, was linearized with Kpn2I (BspMII), and capped cRNA was transcribed in vitro by Sp6 RNA polymerase. Defolliculated oocytes were microinjected with 50 ng of in vitro transcribed cRNA and incubated for 2 to 3 days in a modified Barth's solution containing gentamicin (50 g/ml) at 18°C. Uptake experiments were performed in ND96 solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4) at room temperature. For the Na ϩ -dependent or -independent uptake experiments, we used uptake buffers consisting of 96 mM NaCl, 96 mM LiCl, 96 mM choline chloride, 96 mM N-methyl-D-glucamine, or 96 mM mannitol. Oocytes were incubated in 150 l of the same solution containing radiolabeled substrate for 1 h at room temperature in a 48-well plate, and the uptake was terminated by the addition of ice-cold ND96 solution. The oocytes were washed with the same solution at least five times after transfer to a 24-well plate. The oocytes were solubilized with 10% SDS, and accumulated radioactivity was determined with a liquid scintillation counter. The experiments were repeated with oocytes from at least three to five frogs.
Kinetic Study. Concentration-dependent uptake experiments of [ 3 H]CsA in oocytes expressing IgLC-rG were performed at final concentrations of 1, 50, 100, 200, and 600 nM. [ 3 H]CsA was incubated with oocytes expressing IgLC-rG for 1 h at room temperature, stopped with ice-cold ND96 solution, and washed 5 times as described above. Three oocytes were transferred to one scintillation vial and dissolved in 0.2 ml of 10% SDS. A scintillation cocktail was added, and radioactivity was counted. Counts in the control uninjected oocytes were subtracted from the counts in cRNA-injected oocytes. Data are presented as mean Ϯ S.E.M., except for kinetic constants for which the error represents the error of the fit. K m indicates the Michaelis-Menten constant (nanomolar concentration).
cis-Inhibition Study. For inhibition experiments, oocytes expressing IgLC-rG were incubated for 1 h in ND96 solution containing 500 nM [ 3 H]CsA in the presence or absence of inhibitors at a final concentration of 50 M. Digoxin, azithromycin, theophylline, captopril, and salazosulfapyridine (sulfasalazine, SASP) were directly dissolved in ND96 solution from the stock solution. These inhibitors were dissolved in dimethyl sulfoxide (DMSO) and diluted to a final concentration as described above. The final concentration of DMSO in the assay medium did not exceed 1%.
trans-Stimulatory Effect of CsA, Glutarate, and GSH on the Uptake of [ 3 H]CsA via IgLC-rG. The trans-stimulatory effect of CsA, glutarate, and GSH via IgLC-rG-mediated uptake of [ 3 H]CsA was examined under the following conditions: CsA, glutarate, and GSH were directly dissolved in ND96 solution from the stock solution; oocytes expressing IgLC-rG were preloaded with CsA, glutarate, and GSH at a final concentration of 50 M and incubated for 1 h at room temperature; IgLC-rG-expressing oocytes were then incubated for 1 h in ND96 solution containing 500 nM [ 3 H]CsA. These stock solutions of the stimulator were dissolved in DMSO and diluted to a final concentration as described above. The final concentration of DMSO in the assay medium did not exceed 1%.
Immunohistochemical Analysis. A 5-m wax section of human small intestine was obtained from BioChain Institute, Inc. (San Leandro, CA) and light microscopic immunohistochemical analysis using the streptavidin-biotinhorseradish peroxidase complex technique was carried out (Dako, Carpinteria, CA). Sections were dewaxed, rehydrated, and incubated with 3% H 2 O 2 in 100% methanol to eliminate endogenous peroxidase activity. After rinsing in 0.05 M Tris-buffered saline containing 0.1% Tween 20, sections were treated with 200ϫ diluted (approximately 10 g/ml) polyclonal antibody (amino acids 195-210, SSYLSLTPEQWKSHRS) at 4°C overnight. Thereafter, the sections were incubated with the secondary biotinylated goat polyclonal antibody against rabbit Ig (Dako) with horseradish peroxidase-labeled streptavidin. This step was followed by incubation with diaminobenzidine and hydrogen peroxide. The sections were counterstained with Carrazzi's hematoxylin solution (Wako Pure Chemicals, Tokyo, Japan) and examined under light microscopy.
For the control experiment, the universal negative control rabbit solution (Dako) was used instead of IgLC-rG-specific antibody.
Statistical Analysis. Comparisons of data measuring the initial rates of uptake of [ 3 H]CsA in the presence and absence of inhibitors or stimulators were performed by the unpaired Student's t test or two-way analysis of variance. Kinetic data from experiments measuring the uptake of radiolabeled substrates were fit to the Michaelis-Menten equation by nonlinear least-squares regression analysis with S.E.s derived from these curves.
Results
Using an EST clone (BX327815) as a probe, we screened a cDNA library under a low stringency condition (Umemoto et al., 2009 ) and isolated four positive clones designated the light chain of human Ig surface antigen-related gene, IgLC-rG. These clones had overlapping identical sequences and were 696 base pairs with a single open reading frame encoding a 232-amino acid sequence with a calculated molecular mass of 24.74 kDa (GenBank/EMBL/DDBJ accession number AB369252). There are no consensus sequences for O-and N-glycosylation sites, one consensus sequence for cAMP-and cGMPdependent protein kinase C sites (Ser 207 ), and one consensus sequence for the cAMP phosphorylation site (Arg 70 ) (Fig. 1A ). We found that there is an Ig domain variable region and an Ig domain constant region. In addition, the IgLC-rG amino acid sequence has one Marek's disease glycoprotein A domain.
Kyte and Doolittle hydropathy analysis (window 9) revealed that IgLC-rG is likely to have two transmembrane domains. A similar result was obtained by TMpred analysis (http://www.ch.embnet.org/ software/TMPRED_form.html), suggesting that IgLC-rG may have two transmembrane domains (TMD1 and TMD2) (Fig. 1B) .
When we submitted the amino acid sequence of IgLC-rG to the BLAST program (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAMϭ dmd.aspetjournals.org Downloaded from blastp&BLAST_PROGRAMSϭblastp&PAGE_TYPEϭBlastSearch& SHOW_DEFAULTSϭon&LINK_LOCϭblasthome), several similar sequences were identified. Therefore, we constructed the phylogenic tree using some of these similar sequences in the BLAST program (http:// blast.ncbi.nlm.nih.gov/Blast.cgi) and found that IgLC-rG is positioned between the human Ig light chain and Ig light chain (Fig. 1C) Tissue expression of the mRNA corresponding to IgLC-rG in human various tissues was subsequently examined by Northern blot analysis. As shown in Fig. 2A , two strong 0.7-kb mRNA bands were detected predominantly in the human adult spleen and small intestine. However, no significant 0.7-kb mRNA was detected in other adult tissues[heart, brain (whole), placenta, lung, liver, skeletal muscle, kidney, pancreas, thymus, prostate, testis, ovary, colon, prostate, and peripheral blood leukocytes] and in human fetal tissues ( Fig. 2A) . Thus, the expression of IgLC-rG mRNA in humans was tissuespecific. Based on these observations, we next examined the distribution of IgLC-rG mRNA in mouse tissues by Northern blot analysis elucidate whether there exists a counterpart of this clone. The result is also shown in Fig. 2 . However, no IgLC-rG mRNA was expressed in the male mouse tissues (data not shown). Moreover, we could not detect any bands corresponding to the IgLC-rG gene in any tissues of the guinea pig (data not shown), indicating that the IgLC-rG gene is human-specific. Furthermore, we found that there was no signal detected in several human tumor-derived cell lines such as HL60, HeLa S3, K562, MOLT-4, Raji, SW480, A549, and G361 (Fig. 2B) .
Because the IgLC-rG amino acid sequence is predicted to have two membrane-spanning domains (Fig. 1) To elucidate the transport characteristics of IgLC-rG, we subsequently examined the effect of sodium-, pH-, time-, and concentration-dependent uptake. As shown in Fig. 4A , the uptake of [ 3 H]CsA via IgLC-rG was affected by the replacement of extracellular sodium with choline, lithium, and mannitol. These results indicate that IgLC-rG is sodium-dependent. Pajor (1995) has reported that sodium dicarboxylate cotransporter-1 is a sodiumdependent transporter. Based on this report, we next examined sodium activation of [ 3 H]CsA uptake in oocytes injected with IgLC-rG cRNA. As shown in Fig. 4B , when sodium was removed from the transport buffer and replaced with an equal amount of mannitol, the uptake of [ 3 H]CsA was reduced to control levels. However, when sodium was restored in the transport buffer, trans- Other experimental conditions and details are described under Materials and Methods. HL60, promyelocytic leukemia; HeLa S3, HeLa subcell line 3; K562, chronic myelogenous leukemia; MOLT-4, lymphoblastic leukemia; Raji, Burkitt's lymphoma; SW480, colorectal adenocarcinoma; A549, lung carcinoma; G361, melanoma. 4E ). As illustrated in Fig. 4E , the efflux of [ 3 H]CsA via IgLC-rG was shown in a time-dependent manner up to 90 min. The IgLCrG-mediated efflux of [ 3 H]CsA reached a maximum at approximately 60 min; however, compared with the rates between influx and efflux, the influx rate was much higher (approximately 500 times higher) (Fig. 4A) than the efflux rate, indicating that IgLC-rG does not function as a bidirectional transporter. (Umemoto et al., 2009 ). On the other hand, Mahagita et al. (2007) have reported that GSH has no effect on the uptake or efflux via OATP1B1/OATP-C (SLCO1B1) and/or OATP1B3/OATP-8 (SLCO1B1). Based on their findings, we next examined the trans-stimulatory effect of GSH and glutarate to elucidate whether these endogenous compounds trans-stimulate the transport of [ 3 H]CsA via IgLC-rG. As shown in Fig. 5A To define the substrate specificity of IgLC-rG further, the cisinhibitory effect of various compounds by IgLC-rG-mediated uptake of [ 3 H]CsA was subsequently investigated. As shown in Fig. 5B , we did not observe the cis-inhibitory effects for structurally unrelated compounds. Taken together, these results indicate that IgLC-rG is a sodium-, pH-, and concentration-dependent CsA transporter.
Immunohistochemical analysis was performed to determine the membrane localization of IgLC-rG in the human small intestine. As shown in Fig. 6A , low-power magnification light microscopy of 5-m-thick paraffin-embedded sections demonstrated that there was immunostaining of IgLC-rG in the human small intestine. Under high magnification, IgLC-rG was located on the plasma membrane (Fig.   6B ). By preincubation of normal rabbit serum, the immunoreactivity was diminished (data not shown).
Discussion
The present study describes the isolation and transport characterization of a novel gene encoding the light chain of the human Ig surface antigen-related gene, IgLC-rG. Transport experiments using a Xenopus oocyte expression system revealed that IgLC-rG predominantly transports [ 3 H]CsA in pH-, concentration-, time-, and sodiumdependent manners. The uptake of [ 3 H]CsA via IgLC-rG was transstimulated by GSH and CsA. Although IgLC-rG belongs to the Ig superfamily, the present article is the first evidence concerning the transport of organic solutes via the Ig superfamily-related gene in the human body.
The tissue distribution and the expression of the IgLC-rG gene were first investigated. The expression of IgLC-rG mRNA was predominantly expressed in the spleen and small intestine in human adult tissues, whereas expression in other tissues of the human body was low or none; therefore, we chose some human tissues (brain, liver, kidney, and placenta) and performed reverse transcription-PCR analysis to confirm whether the IgLC-rG gene is expressed. Although a faint PCR product was detected in the liver and kidney, no PCR product was found in the brain and placenta (data not shown), indicating that the expression of IgLC-rG mRNA is tissue-specific.
During the early period after birth, the gastrointestinal tract (e.g., small intestine) undergoes a complex process of growth and differentiation. Jenkins et al., (2003) (FcRn), and polymeric IgA receptors (pIgR), an apical sodium-dependent bile acid transporter (SLC10A2), and an Na ϩ /glucose cotransporter (SLC5A1) are expressed in enterocytes. Except for lactase, these proteins are gradually increased with each day after birth and are developmentally regulated by postnatal development. Likewise, the mucosal adaptive immune systems also undergo dramatic changes during early postnatal development (Allan and Gleeson, 1999) . Although we have not determined the precise mechanism of the ontogenic differences between adults and the fetus concerning IgLC-rG gene expression in the small intestine, several studies have suggested that other external stimuli, such as food intake, may also influence the precise timing and the level of expression of specific intestinal immune systems and protein development. Therefore, environmental changes and local stimuli functioning together may be responsible for initiating the expression of IgLC-rG gene in the small intestine. We also observed that IgLC-rG mRNA is not expressed in tumor-derived cell lines, suggesting that IgLC-rG may not be involved in the high protein synthesis for activation or growth in cancer cells.
As mentioned above, transporters such as OATP/Oatp (SLCO21A/ Slco21a), OAT/Oat (SLCO22A/Slco22a), 4F2hc (SLC3A2), related to b 0,ϩ amino acid transporter (D2) (SLC3A1), and Niemann-Pick C1-like 1 have several membrane-spanning domains, and these transporters, specifically the OAT and the OATP families, mediate a wide range of organic drugs and chemicals (Bertran et al., 1992a,b; Lee et al., 1993; Hagenbuch and Meier, 2003; Koepsell and Endou, 2004; Iyer et al., 2005) . One possible structural signature for producing the transport activity seems to require the membrane-spanning domain(s). Therefore, we examined the secondary model of IgLC-rG using a Kyte and Doolittle hydropathy analysis and found that IgLC-rG was predicted to have two membrane-spanning domains. On the basis of this finding together with published findings, we assumed that the isolated cDNA clone may have a transport function; therefore, IgLCrG-cRNA-injected oocytes were used for transport characterization. We were surprised to find that IgLC-rG mediates the high-affinity transport of [ 3 H]CsA in Na ϩ -, pH-, time-, and concentration-dependent manners. Furthermore, we observed that oocytes expressing IgLC-rG do not transport PAH, TEA, and [SCAP]L-carnitine, suggesting that either anionic or cationic moieties would not be necessary for the transport recognition of IgLC-rG.
To elucidate the substrate selectivity of IgLC-rG, based on these findings, uptake experiments were subsequently performed using several radiolabeled compounds. However, we observed that DEX, 6-MP, VC, theophylline, MTX, valproate, and allopurinol did not transport IgLC-rG; IgLC-rG, however, transported CsA. These find- ings lead us to conclude that CsA is a predominant substrate of IgLC-rG and may be the molecule responsible for the transport of CsA in the human body. Wang et al. (2001) and Seward et al. (2003) have revealed that both organic solute transporter ␣ (Ost␣) and organic solute transporter ␤ (Ost␤) transport prostaglandin E 2 (PGE 2 ) and taurocholate. Because steroids and eicosanoids are involved in many cellular functions, it would be interesting to elucidate whether some steroids (estron-3-sulfate, dehydroepiandrosterone sulfate, and taurocholate) and eicosanoids (PGE 2 and PGF 2␣ ) are transported by IgLC-rG.
Several endogenous compounds have been identified as the driving force of drug transporters. Sekine et al. (1997) and Sweet et al. (1997) have reported that dicarboxylate is an endogenous substrate of rat Oat1 (Slc22a6) indicating that that rat Oat1 (Slc22a6) acts as an organic anion/dicarboxylate exchanger. Dicarboxylates also act as the driving force of sodium dicarboxylate cotransporter-1 (Slc13a2) as reported by Pajor (1995) . In addition, GSH is a substrate of Oatp1 (Slco1a1), resulting in the transport of several drugs and chemicals as an exchange mechanism (Li et al., 2000) , and Bahn et al. (2008) have revealed that human OAT10 (SLC22A13)-mediated uptake of [ 14 C]urate is trans-stimulated by glutathione. To elucidate the driving force of IgLC-rG, based on these findings, we tested CsA, glutarate, and GSH. We found that a trans-stimulatory effect was observed with the addition of GSH and CsA, indicating that both compounds function as the driving force of IgLC-rG-mediated uptake and may act as a CsA/GSH exchanger in the human body.
Two conserved heterodimer interface domains (http://www.ncbi. nlm.nih.gov/Structure/cdd/cdd.shtml) can be found on the IgLC-rG amino acid sequence. However, the Ost␣-Ost␤ complex produced the maximum velocity as a drug transporter (Dawson et al., 2005) , indicating that both proteins are necessary to produce the transport activity. Taking these facts into consideration, it is not clear at this time whether the IgLC-rG protein functions as a heterodimer or heterooligomer to form the active transport molecule. Although phylogenic tree analysis indicated that IgLC-rG is a member of the Ig light chain superfamily and Ig consists of two units (light and heavy chains), it would be interesting to elucidate whether this protein is required for the heavy chain such as 4F2hc (CD98) for LAT1 (Kanai et al., 1998) or whether the transport of CsA via IgLC-rG is a single transport system. In addition, it would be interesting to know whether IgLC-rG is coupled to other unidentified proteins. In vitro translation experiments would resolve this subject, or additional experiments involving the expression of IgLC-rG in transformed cell lines would better define the transport system for this clone.
We subsequently studied the cis-inhibitory effect of IgLC-rGmediated uptake by several organic anions to clarify further the precise substrate selectivity. The transport of [ 3 H]CsA mediated by IgLC-rG did not interact with any compounds such as digoxin, azithromycin, theophylline, captopril, and SASP. Because some of these drugs are known to across the plasma membrane via OATP4C1 [OATP-H (SLC21A20)] (Mikkaichi et al., 2004) or human OAT2 (SLC22A7) (Kobayashi et al., 2005) , our results indicate that, at least partly, these drugs may not be candidates for the substrate of IgLC-rG.
Several investigators have shown that drug transporters such as peptide transporter-1 (SLC15A1) (Liang et al., 1995) , monocarboxylate transporter 1 (SLC16A1) (Kim et al., 1992) , OATP1A2/2B1 (SLCO1A2/2B1) (Kullak-Ublick et al., 1995) , organic cation transporter novel 1/2 (SLC22A4/22A5) (Tamai et al., 1997; Wu et al., 1998) , OCT3 (SLC22A3) (Kekuda et al., 1998) , and Niemann-Pick C1-like 1 (Narushima et al., 2008) are expressed in the apical membrane of the small intestine. However, none of these transporters transport CsA. In consideration of these articles and our uptake experiments, IgLC-rG may play an important role in the intestinal handling of CsA.
Many kinds of drugs interact with CsA. Tacrolimus (FK506) has been used as a potent immunosuppressive drug for treatment of graft rejection in organ transplant patients or for treatment of several autoimmune diseases such as arthritis and atopic dermatitis (http://www.info.pmda.go.jp/psearch/ html/menu_tenpu_base.html). It is known that tacrolimus is metabolized by CYP3A4 (Shiraga et al., 1994) . On the other hand, CsA is a substrate of CYP3A4; therefore, with the concomitant administration of both drugs, some contraindications could be observed in the clinical setting. To elucidate the mechanism of the transporter-mediated interaction of CsA with tacrolimus, we tested the concentration-dependent trans-stimulatory effect of tacrolimus on the uptake of [ 3 H]CsA (data not shown). However, no trans-stimulatory effect was observed even at the highest concentration (10 M), suggesting that IgLC-rG is not involved in the CsA-tacrolimus drug interaction.
For a comprehensive understanding of the role of IgLC-rG in the human body, we used a paraffin-embedded human small intestine and performed immunohistochemical analysis to determine the membrane localization of IgLC-rG. We found that IgLC-rG was localized on the apical membrane site of the human small intestine, suggesting that IgLC-rG acts as the entry of CsA from gastrointestinal contents into the bloodstream.
In conclusion, we describe the cloning and pharmacological characterization of a novel human gene, IgLC-rG. Phylogenic tree analysis revealed that the amino acid sequence of IgLC-rG is positioned within a member of the Ig light chain superfamily. Therefore, our results are expected to facilitate research on the discovery of the novel function of membrane-anchored protein in the human body. In addition, our results may lead us to a new strategy to maximize the therapeutic efficacy and to minimize toxicity when targeting the IgLC-rG gene or its gene product in patients with autoimmune diseases or for treatment of graft rejection in organ transplant patients before and after the administration of CsA.
